<DOC>
	<DOCNO>NCT02386150</DOCNO>
	<brief_summary>This study seek determine safety immunogenicity series 3 primary vaccination booster vaccination Recombinant ricin toxin A-chain 1-33/44-198 ( rRTA 1-33/44-198 ) vaccine ( RVEc ) 10 20 μg intradermally ( ID ) . This study evaluate RVEc display acceptable safety profile determine adverse event ( AE ) data RVEc elicit anti-ricin antibody titer ricin toxin-neutralizing antibody vaccine recipient .</brief_summary>
	<brief_title>ID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ — 3-Dose Primary Series With Boost</brief_title>
	<detailed_description />
	<mesh_term>Poisoning</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Study participant must read sign approve informed consent . Study participant must least 18 year old time screen old 50 year old time first study vaccination . Participants must weigh least 110 pound time screen . Participants must good health judge medical history , physical examination , electrocardiogram , chest xray , hematology , clinical chemistry , urinalysis , hepatitis serology , human immunodeficiency virus ( HIV ) antibody test must medically clear participation investigator . Females childbearing potential must negative pregnancy test screen morning vaccination prior receipt vaccine must agree use highly effective method birth control screen 3 month follow last study vaccination . A highly effective method birth control define one failure rate le 1 % per year . Acceptable birth control method meet criterion include hormonal implant injectables , combine oral contraceptive , intrauterine device , female sterilization ( tubal ligation ) , sexual abstinence , vasectomized partner . Female participant must also agree breastfeed screen 3 month follow last study vaccination . Study participant must willing return followup visit . Study participant must agree report adverse event ( AE ) may may associate administration investigational product duration study participation . Study participant must agree abstain excessive exercise ( usual routine ) excessive alcohol consumption ( exceed 2 drink male exceed 1 drink female daily binge drink ) duration study participation . Acute chronic medical condition immunodeficiency medical condition medical treatment , medication , dietary supplement , investigator 's opinion , would impair subject 's ability respond vaccination . Use corticosteroid , inhale topical corticosteroid eye drop , permit . Severe hypersensitivity vaccine . History asthma , chronic obstructive pulmonary disease , current/residual disease lung . Clinically significant abnormal laboratory test . ( Normal reference range determine local clinical laboratory . ) Current smoker , include use electronic cigarette . Any known allergy sodium succinate , Polysorbate 20 ( detergent ) , Alhydrogel , kanamycin . Receipt vaccine investigational product within 30 day vaccination RVEc ( exception inactivate influenza vaccine receive least 30 day RVEc Dose 3 4 ) . Creatine phosphokinase level consistently elevate 2 × normal . Previous vaccination RVEc ricin vaccine candidate route .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>